Detail for EpCAM

Full Name

Epithelial cell adhesion molecule

Uniprot ID

Gene Name



Related Disease

  • Pancreatic Cancer [ref.1-4]
  • Prostate Cancer [ref.5]

Therapy Method


May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E.

Related Pathway/CSCs feature

  • Epithelial-Mesenchymal Transition
  • FoxM1 signaling pathway


  • [1] Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells.
    Bao, B., et al. (2011). J Cell Biochem 112(9): 2296-2306.. [ 21503965 ]
  • [2] Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment.
    Bao, B., et al. (2012). PLoS One 7(12): e50165.. [ 23272057 ]
  • [3] Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression.
    Bao, B., et al. (2012). Cancer Res 72(1): 335-345.. [ 22108826 ]
  • [4] EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.
    Cioffi, M., et al. (2012). Clin Cancer Res 18(2): 465-474. [ 22096026 ]
  • [5] Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
    Deng, Z., et al. (2015). BMC Immunol 16: 1. [ 25636521 ]

Back to top